NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

"The DCVax-L MAA (commercial application) is a massive, multi-year review process that is already underway. The company may be submitting the New IND/IMPD for DCVax-Direct separately and sooner, as it is a required step to launch new clinical trials."

This part of the analysis by Gemini is concerning as it implies that NWBO may not be
able to use the EDEN's automatic manufacturing methodology for some time and therefore
DCVax-L production will still depend post approval on the artisan method for a
considerable amount of time.